NZ589844A - Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors - Google Patents

Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors

Info

Publication number
NZ589844A
NZ589844A NZ589844A NZ58984409A NZ589844A NZ 589844 A NZ589844 A NZ 589844A NZ 589844 A NZ589844 A NZ 589844A NZ 58984409 A NZ58984409 A NZ 58984409A NZ 589844 A NZ589844 A NZ 589844A
Authority
NZ
New Zealand
Prior art keywords
pi3k
phosphatidylinositol
thiophene
kinase
inhibitors
Prior art date
Application number
NZ589844A
Other languages
English (en)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ589844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ589844A publication Critical patent/NZ589844A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ589844A 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors NZ589844A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
NZ589844A true NZ589844A (en) 2012-11-30

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ589844A NZ589844A (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors

Country Status (21)

Country Link
US (3) US8183240B2 (OSRAM)
EP (1) EP2313399B1 (OSRAM)
JP (1) JP5596026B2 (OSRAM)
KR (1) KR20110018451A (OSRAM)
CN (1) CN102066365A (OSRAM)
AU (1) AU2009260782B2 (OSRAM)
BR (1) BRPI0914223A2 (OSRAM)
CA (1) CA2727069A1 (OSRAM)
CL (1) CL2010001474A1 (OSRAM)
CO (1) CO6331431A2 (OSRAM)
CR (1) CR20110032A (OSRAM)
EA (1) EA201170052A1 (OSRAM)
ES (1) ES2491522T3 (OSRAM)
GE (1) GEP20125650B (OSRAM)
IL (1) IL210055A0 (OSRAM)
MA (1) MA32468B1 (OSRAM)
MX (1) MX2010014125A (OSRAM)
NZ (1) NZ589844A (OSRAM)
UA (1) UA106206C2 (OSRAM)
WO (1) WO2009154741A1 (OSRAM)
ZA (1) ZA201008875B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
AU2009260782B2 (en) * 2008-06-19 2014-12-11 Millennium Pharmaceuticals, Inc. Thiophene or thiazole derivatives and their use as PI3K inhibitors
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2012021615A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY33554A (es) 2010-08-11 2012-02-29 Millennium Pharm Inc Heteroarilos y usos de los mismos
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
BR112013009166A2 (pt) 2010-10-13 2016-07-26 Millennium Pharm Inc heteroarilas e uso das mesmas.
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
IN2014DN06898A (OSRAM) 2012-03-14 2015-05-15 Salk Inst For Biological Studi
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
RU2016136091A (ru) * 2014-02-14 2018-03-19 Дзе Юниверсити Оф Бритиш Коламбиа Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2020261144A1 (en) * 2019-06-28 2020-12-30 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
PE20221327A1 (es) 2019-12-20 2022-09-09 Bayer Ag Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
CA2565965A1 (en) * 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
US20090076009A1 (en) 2006-05-03 2009-03-19 Arnould Jean-Claude Retired Thiazole derivatives and their use as anti-tumour agents
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
CA2704711C (en) * 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
EP2250160B1 (en) * 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
AU2009260782B2 (en) * 2008-06-19 2014-12-11 Millennium Pharmaceuticals, Inc. Thiophene or thiazole derivatives and their use as PI3K inhibitors

Also Published As

Publication number Publication date
EP2313399A1 (en) 2011-04-27
WO2009154741A8 (en) 2010-03-25
CL2010001474A1 (es) 2011-04-29
JP5596026B2 (ja) 2014-09-24
UA106206C2 (ru) 2014-08-11
ZA201008875B (en) 2012-02-29
EP2313399B1 (en) 2014-05-28
US20130217689A1 (en) 2013-08-22
US8440664B2 (en) 2013-05-14
ES2491522T3 (es) 2014-09-08
AU2009260782B2 (en) 2014-12-11
EA201170052A1 (ru) 2011-06-30
CO6331431A2 (es) 2011-10-20
CA2727069A1 (en) 2009-12-23
JP2011524904A (ja) 2011-09-08
CN102066365A (zh) 2011-05-18
MA32468B1 (fr) 2011-07-03
BRPI0914223A2 (pt) 2019-09-24
US8183240B2 (en) 2012-05-22
WO2009154741A1 (en) 2009-12-23
MX2010014125A (es) 2011-02-24
US20120202812A1 (en) 2012-08-09
IL210055A0 (en) 2011-02-28
AU2009260782A1 (en) 2009-12-23
GEP20125650B (en) 2012-09-25
US20100075951A1 (en) 2010-03-25
KR20110018451A (ko) 2011-02-23
CR20110032A (es) 2011-03-14

Similar Documents

Publication Publication Date Title
NZ589844A (en) Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
PH12013500274A1 (en) Heteroaryls and uses thereof
WO2010003475A3 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
MX340714B (es) Inhibidores de hsp90.
HRP20180662T1 (hr) 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
GEP20125652B (en) cMET INHIBITORS
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
UA107784C2 (en) Inhibitor of melanin production
WO2009156041A3 (de) Thiazolyl-piperidinderivate
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
ZA200908612B (en) 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
ZA201007253B (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
MX2012000178A (es) 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
MX2013003498A (es) Derivados de cromeno.
MX2011007232A (es) Derivados de benzotiazolona.
UA106628C2 (uk) Метилпіролопіримідинкарбоксаміди
MX2011007641A (es) Nuevos compuestos heterociclicos como inhibidores de metap-2.
TN2013000055A1 (en) Heteroaryls and uses thereof
HK1156520A (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 JUN 2016 BY HENRY HUGHES

Effective date: 20130604

LAPS Patent lapsed